Pregnancy after the diagnosis of breast cancer is an important survivorship issue. We conducted a retrospective analysis that included 32 premenopausal women with a diagnosis of estrogen receptor-positive breast cancer and subsequent pregnancy and an age-and stage-matched control cohort without subsequent pregnancy. The results of the present study did not demonstrate poorer disease-free survival in women who became pregnant within 5 years after their cancer diagnosis. Background: Counseling patients regarding the risk of future pregnancy on hormone receptor-positive breast cancer outcomes is difficult because of the minimal data and understanding of pregnancy on the breast environment.
Introduction
Breast cancer is the most commonly diagnosed malignancy in women aged 30 to 45 years, and this age group accounts for 10.8% of newly diagnosed breast cancer cases annually in the United States. 1 With the trend of women delaying pregnancy and childbirth until later in life, fertility preservation after a diagnosis of breast cancer and future pregnancy is a growing concern. 2 Although great advancements have been made in fertility preservation for cancer patients, many women and their physicians are hesitant to consider or recommend pregnancy with a history of hormone receptor-positive breast cancer, and many patients are recommended against future pregnancy. 3 Although the potential for negative consequences resulting from the increased hormonal milieu associated with pregnancy is of high theoretical concern to physicians, no data have suggested that pregnancy after a diagnosis of breast cancer is associated with a greater rate of recurrence or death. Furthermore, limited data are available on the risk of breast cancer recurrence after pregnancy since tamoxifen became the standard of care for adjuvant therapy for hormone receptor-positive breast cancer and significantly improved outcomes. We investigated the breast cancer outcomes of premenopausal women diagnosed with hormone receptor-positive breast cancer at our cancer center during the tamoxifen era, who subsequently became pregnant within 5 years after their breast cancer diagnosis.
Patients and Methods
The patients included in the pregnancy cohort were premenopausal women, aged ! 18 years with a diagnosis of breast cancer. The histologic types included ductal carcinoma in situ, invasive ductal carcinoma, and invasive lobular carcinoma that was stage 0 to IIIA (Tis-T3N0-N2). The tumor had to have been estrogen receptor-positive (> 1%). Also, all included women had to have been considered for adjuvant tamoxifen therapy. The women in the pregnancy cohort must have achieved a pregnancy (including miscarriage) within 5 years after the diagnosis of breast cancer.
The patients in the control (no pregnancy) cohort were also premenopausal women, aged ! 18 years, with a diagnosis of stage 0 to IIIA, estrogen receptor-positive breast cancer. Using the Northwestern Medicine Enterprise Data Warehouse, the control group was matched by age and stage to the pregnancy cohort. However, these patients had not achieved a pregnancy within 5 years after the diagnosis of breast cancer. All included women had been considered for adjuvant tamoxifen therapy.
A query was conducted in the Northwestern Medicine Enterprise Data Warehouse to identify female patients aged ! 18 years at the diagnosis of breast cancer (International Classification Diagnosis [ICD] code, 174.X) or ductal carcinoma in situ (ICD code, 233.0) and a subsequent diagnosis of pregnancy (ICD, 9th revision, code, V22.2 or alternative pregnancy code) within 5 years after the breast cancer diagnosis who had been seen at Northwestern University Hospital from 2000 to 2010. A review of the patients' electronic medical records was conducted to identify patients who met the inclusion criteria and obtain data on the included patients regarding diagnosis, tumor characteristics and staging, treatment history, pregnancy history, and outcomes. Disease recurrence included local and metastatic disease.
For the statistical analysis, categorical variables were summarized using frequencies and percentages and compared between groups using Fisher's exact test. Continuous variables were summarized using the mean, standard deviation, median, and range and compared between groups using the Wilcoxon rank sum test. Disease-free survival (DFS) was summarized using Kaplan-Meier curves and compared between groups using the log-rank test.
Results
Of the 61 patients, 32 were included in the pregnancy cohort and 29 in the control (no pregnancy) cohort. No statistically significant difference was found in age, diagnosis, stage, tumor grade, or HER2 status between the 2 groups. More tumors in the control (no pregnancy) cohort had progesterone receptor-positive disease, 27 (93%) compared with 21 (70%) in the pregnancy cohort (P ¼ .042). The patient and tumor characteristics are listed in Table 1 .
The surgical interventions were similar between the cohorts, with a trend toward contralateral prophylactic mastectomy in the control (no pregnancy) cohort. However, the difference was not statistically significant. Adjuvant therapy was also similar between the 2 groups, including those who received adjuvant endocrine therapy and radiation therapy. The recurrence score, as analyzed using the 21-gene reverse transcription-polymerase chain reaction assay, and chemotherapy details were not available for most patients and, therefore, were not included in the present review. Of the 32 women included in the pregnancy cohort, 19 (63%) received endocrine therapy. In the control (no pregnancy) cohort, 23 of the 29 women (82%) received endocrine therapy (P ¼ .25). Women were considered to have received endocrine therapy (tamoxifen) even if initiation of treatment was delayed, interrupted, or discontinued because of pregnancy. The treatment interventions are summarized in Table 2 . The mean duration of endocrine therapy was significantly longer in the control (no pregnancy) cohort at 42.3 months (range, 0-120 months) compared with that in the pregnancy cohort (mean, 20.9 months; range, 0-72 months; P ¼ .008).
The follow-up duration was shorter in the control (no pregnancy) cohort (mean, 78 months; range, 23-168 months) than in the pregnancy cohort (mean, 110 months; range 57-185 months; P ¼ .005). No statistically significant difference was found in the incidence of breast cancer recurrence between the women who became pregnant within 5 years after the diagnosis of breast cancer and those who did not. Four women (14%) in the control (no pregnancy) cohort experienced breast cancer recurrence compared with 8 women (26%) in the pregnancy cohort (P ¼ .34). In the pregnancy cohort, 19 of 32 women took adjuvant tamoxifen (63%). Of these women, 7 took adjuvant tamoxifen before the subsequent pregnancy and did not resume after pregnancy, 6 women delayed e186 -Clinical Breast Cancer July 2017
Breast Cancer Outcomes and Subsequent Pregnancy tamoxifen until after the subsequent pregnancy, and 6 women took tamoxifen before pregnancy, withheld it during the pregnancy, and resumed it to complete adjuvant tamoxifen therapy after pregnancy and breast feeding. In the pregnancy cohort, 8 women experienced breast cancer recurrence, 3 of which developed > 5 years after the diagnosis. For 1 patient, it was not clear whether she had developed recurrence or a new primary triple-negative tumor. One half of the women with subsequent pregnancy and recurrence had not taken adjuvant tamoxifen, 1 had taken tamoxifen for 6 months and developed recurrence during her subsequent pregnancy, and 3 women with recurrence had taken tamoxifen for 18, 24, and 27 months before their subsequent pregnancy. For women who did not become pregnant within 5 years after their breast cancer diagnosis, the 5-year DFS rate was 92% (95% CI, 81%-100%). For women who did achieve pregnancy within 5 years after their diagnosis of breast cancer, the 5-year DFS rate was 84% (95% CI, 72%-97%). No statistically significant difference was found in the 5-year DFS rate for women who became pregnant within 5 years after the diagnosis of hormone-positive breast cancer compared with women who did not become pregnant within 5 years after their diagnosis (P ¼ .69; Figure 1 ).
Discussion
Several retrospective analyses and meta-analyses have been performed to address the question of cancer outcomes after breast cancer and subsequent pregnancy. These analyses demonstrated no adverse effect on overall survival; however, much of these data are from the pre-tamoxifen era. [4] [5] [6] [7] The International Breast Cancer
Study Group conducted a retrospective study of patients enrolled in their previous International Breast Cancer Study Group trials (trials V, VI, and VIII) who subsequently became pregnant after diagnosis. The International Breast Cancer Study Group compared these women with women in the database who had not become pregnant, matching for nodal status, tumor size, age, and year of diagnosis. 3 The women who subsequently became pregnant did not have worse 5-or 10-year overall survival compared with women who did not become pregnant. In a cohort study using population-based cancer registries linked to birth certificate data in 3 major US cities, women with a diagnosis of breast cancer and a subsequent documented birth were compared with age-, stage-and racematched women, and mortality was assessed. 8 No increased risk of mortality was found in their analysis, and the women with a birth occurring ! 10 months after their diagnosis of breast cancer had a decreased risk of mortality (relative risk, 0.54). This might, in part, have been associated with a healthy mother effect, which has been attributed to pregnancy in many studies. A subset analysis did find that women with features associated with high-risk breast cancer, such as larger tumors, lymph node-positive disease, or requiring chemotherapy, did have a greater risk of mortality. Overall, no increased risk of mortality was found with subsequent pregnancy. Blakely et al 5 conducted a retrospective analysis of women diagnosed with invasive breast cancer at age 35 years at their Cancer Center in Houston, Texas and the effect of subsequent pregnancy on outcomes. Estrogen receptor data were not available for one third of patients; however, of the remaining patients, only 41% had estrogen receptor-positive disease. In their study, the women who subsequently became pregnant after their breast cancer diagnosis did not demonstrate an increased risk of breast cancer recurrence or worse overall survival. Although retrospective data are available demonstrating no increased risk of recurrence or mortality with pregnancy after breast cancer, these analyses did not specifically consider a hormone receptor-positive cohort or use a control cohort of women who had received, or had at least been offered, adjuvant tamoxifen therapy, which is now the standard of care and associated with a 30% to 50% decrease in breast cancer recurrence. 9, 10 We acknowledge that premenopausal women diagnosed with breast cancer are more likely to present with hormone receptor-negative disease compared with older women; however, two thirds of young premenopausal women will still have estrogen receptorpositive tumors 11 and should be offered tamoxifen. It is understandably difficult for physicians to counsel their patients on the risk of withholding tamoxifen for childbearing, because tamoxifen is contraindicated during pregnancy, with limited data available on the outcomes of breast cancer after subsequent pregnancy in the tamoxifen era. As a part of a multicenter retrospective study, Azim et al 12 assessed the influence of hormone receptor status on breast cancer outcomes in women with subsequent pregnancy after a Fertility preservation 2 (7) 3 (10) .99
Data presented as n (%) or mean AE standard deviation. Data on endocrine therapy is missing on one patient in the control group and one patient in the pregnancy group. a All patients were offered endocrine therapy. 
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Clinical Breast Cancer July 2017 -e187 diagnosis of breast cancer compared with women who did not become pregnant. Azim et al 12 found no difference in DFS stratified by tumor hormone status. 12 In the present study, only 26% to 27% of patients were treated with antihormone therapy at some point during their disease course. The low use of adjuvant tamoxifen resulted largely from the timing, with the data collected before tamoxifen became the standard of care in the management of earlystage, hormone receptor-positive breast cancer. Also causing an intellectual dilemma for physicians counseling their patients are recent investigations supporting strategies to further decrease endogenous estrogen exposure after a diagnosis of breast cancer, either by extension of adjuvant antihormone therapy or ovarian suppression or ablation in young women. Both the ATLAS (adjuvant tamoxifen longer against shorter) and the aTTom (adjuvant tamoxifeneto offer more?) trials demonstrated potential benefit in recurrence and mortality with continuing tamoxifen for 10 years in patients with estrogen receptor-positive breast cancer. 13, 14 The SOFT (Suppression of Ovarian Function Trial) data showed that although no benefit was realized with ovarian suppression or ablation in the overall study population of women with early-stage, hormone receptor-positive breast cancer treated with tamoxifen, a benefit was seen in women aged < 35 years who remained premenopausal after chemotherapy. 15 The TEXT (tamoxifen and exemestane trial) data further supported ovarian suppression by demonstrating a DFS benefit for women treated with adjuvant exemestane plus ovarian suppression versus tamoxifen plus ovarian suppression. 16 The concept of extending the time of antiestrogen exposure or inducing a postmenopausal state contradicts the concept of the safety of pregnancy (and its associated hormonal milieu) after a diagnosis of breast cancer, although little is understood regarding the effects of pregnancy on the microenvironment in the breast and whether pregnancy might provide a protective effect. Some have hypothesized that the steep decrease in estrogen levels after pregnancy can cause apoptosis in breast cells, and others have demonstrated a reduction in estrogen receptor expression in pregnant women that might protect against breast cancer.
17,18
Our retrospective investigation did not demonstrate a difference in breast cancer recurrence in women who became pregnant within 5 years after their diagnosis of early-stage breast cancer compared with women who did not become pregnant within 5 years of their diagnosis. Many women had interrupted their adjuvant endocrine therapy to become pregnant and breast feed after pregnancy and later returned to complete the standard 5 years of therapy. Overall, however, women in the pregnancy cohort had a shorter length of endocrine therapy than that of the women in the control (no pregnancy) cohort, despite the control cohort having a shorter follow-up length. We recognize the limitations of the retrospective design of our study, including selection and information bias. Our sample size was small, and details on the influence of parity and treatment, including the length of endocrine therapy, would be better addressed in prospective trials or registries with larger sample sizes and longer followup periods. A sampling bias could also have been present, in that healthy women might be more likely to achieve pregnancy, and this could potentially influence their breast cancer outcome.
The issue of pregnancy after a diagnosis of breast cancer is an important factor in cancer survivorship, and more information is needed to counsel our patients. Pagani et al 19 recently reported data from a survey of young patients with breast cancer regarding fertility concerns and interest in a future study of endocrine therapy interruption to allow for pregnancy, in which many women were interested. Based on this information, the Alliance A221405 POSITIVE (pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer) trial was designed. It is a prospective phase II trial investigating breast cancer outcomes with endocrine therapy interruption after breast cancer diagnosis to allow for pregnancy.
Conclusion
We did not demonstrate a difference in breast cancer recurrence in premenopausal women with early-stage estrogen receptor-positive breast cancer who became pregnant within 5 years after their breast cancer diagnosis compared with women who did not become pregnant during that time. Our study was designed using a period that would only include women with a diagnosis of breast cancer during the era when adjuvant endocrine therapy was the standard of care at our institution. All women included were offered adjuvant endocrine therapy, which makes the present study unique from previous retrospective analyses. Although our findings are consistent with other reports that failed to identify a difference in outcomes based on subsequent pregnancy, the sample sizes were small and caution should be exercised in interpreting these data. Further prospective investigation will be beneficial to both patients and physicians in discussions of pregnancy as a key survivorship issue. We believe young women desiring pregnancy after a breast cancer diagnosis should be well informed of the available data and the continued investigation into understanding the influence of pregnancy on breast cancer recurrence risk.
Clinical Practice Points
Breast cancer is the most commonly diagnosed malignancy in premenopausal women aged > 30 years, and with a trend for women delaying pregnancy and childbearing until later in life, future pregnancy is of increasing concern. Several retrospective analyses and meta-analyses have addressed the question of cancer outcomes after breast cancer and subsequent pregnancy and have demonstrated no adverse effect on overall survival. However, most of the available data were collected before adjuvant tamoxifen was the standard of care for hormone-positive breast cancer and had significantly improved the outcomes. Tamoxifen is contraindicated during pregnancy; thus, women should discontinue tamoxifen to achieve pregnancy and for breast feeding. To the best of our knowledge, no studies have specifically addressed the outcomes of women with estrogen receptorpositive breast cancer. The present study did not demonstrate worse 5-year DFS in women who became pregnant within 5 years after their diagnosis of hormone receptor-positive breast cancer despite a shorter mean length of endocrine therapy. The data from a survey by Pagani et al 19 showed that young patients with breast cancer are interested in a future study of endocrine therapy interruption to allow for pregnancy.
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The ongoing Alliance A221405 POSITIVE trial will address this question in a prospective phase II study investigating breast cancer outcomes with endocrine therapy interruption after breast cancer diagnosis to allow for pregnancy. Until those findings are available, our results will help inform patients and physicians as they make decisions regarding future fertility and pregnancy.
